Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Acquisitions & Divestments (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Change in Acquisitions & Divestments for 13 consecutive years, with $252.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 68.03% year-over-year to $252.3 million, compared with a TTM value of $1.0 billion through Dec 2025, up 26.26%, and an annual FY2025 reading of $1.0 billion, up 26.26% over the prior year.
  • Change in Acquisitions & Divestments was $252.3 million for Q4 2025 at Agios Pharmaceuticals, down from $272.1 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $368.7 million in Q1 2024 and bottomed at $134.0 million in Q1 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $225.1 million, with a median of $209.3 million recorded in 2021.
  • The sharpest move saw Change in Acquisitions & Divestments surged 147.84% in 2022, then crashed 55.06% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $336.9 million in 2021, then crashed by 40.97% to $198.9 million in 2022, then fell by 6.38% to $186.2 million in 2023, then decreased by 19.36% to $150.1 million in 2024, then surged by 68.03% to $252.3 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for AGIO at $252.3 million in Q4 2025, $272.1 million in Q3 2025, and $220.6 million in Q2 2025.